Key facts
- Arpeggio’s last known valuation is $41.0M (Nov 2025).
- It has raised $47.6M; the latest was Later Stage VC ($24.1M) in Nov 2025.
- Notable investors include Y Combinator, Khosla Ventures, FundersClub, Fifty Years, Tau Ventures — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Arpeggio
- ·The full record, as it builds
Funding rounds
No funding rounds for Arpeggio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Arpeggio
Developer of a drug assessment technology designed to study mechanistic understanding of how drugs work. The company's technology combines its proprietary biological assay and machine learning algorithms that permit rapid high-resolution snapshots of cellular dynamics following drug treatment, enabling medical scientists to identify new drug targets and improve customers' likelihood of success when they advance new drugs into the clinic.
- Sector
- Healthcare
- HQ
- Boulder, CO, United States
- Founded
- 2017
- Employees
- 10
- Website
- arpeggiobio.com/
- Ownership
- Privately Held (backing)
Arpeggio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arpeggio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arpeggio in its N-PORT filings yet. We sweep new filings monthly.